|
Clinical Trial Stage Projects |
Clive Svendsen |
Human Neural Progenitors Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis |
$6,154,067 |
|
Tools and Technologies II |
Clive Svendsen |
Use of iPS cells (iPSCs) to develop novels tools for the treatment of spinal muscular atrophy. |
$1,933,022 |
|
SPARK |
Veronica Garcia |
Mentored High School Summer Research Program |
$310,023 |
|
Early Translational IV |
Dan Gazit |
Gene Targeting to Endogenous Stem Cells for Segmental Bone Fracture Healing |
$5,121,514 |
|
Inception - Discovery Stage Research Projects |
Dmitriy Sheyn |
IVD rejuvenation using iPSC-derived notochordal cells |
$241,992 |
|
Disease Team Therapy Planning I |
Dan Gazit |
Genetically Engineered Mesenchymal Stem Cells for the Treatment of Vertebral Compression Fractures. |
$107,622 |
|
Inception - Discovery Stage Research Projects |
Linda Cambier |
Exosomal Y-RNAs as mediators of bioactivity of cardiac-derived cell therapy |
$181,063 |
|
Research Leadership |
Barry Stripp |
Epithelial progenitors and the stromal niche as therapeutic targets in lung disease |
$4,841,830 |
|
Clinical Trial Stage Projects |
Clive Svendsen |
Clinical Study to Assess Safety and Efficacy of Subretinal Injection of Human Neural Progenitor Cells for Treatment of Retinitis Pigmentosa |
$10,444,063 |
|
Disease Team Therapy Planning I |
Clive Svendsen |
Stem Cells Secreting GDNF for the Treatment of ALS |
$63,487 |
|
Inception - Discovery Stage Research Projects |
Clive Svendsen |
Blood Brain Barrier (BBB)-on-Chip: Development and validation of a novel iPS-based microfluidic model of the human BBB |
$241,992 |
|
Basic Biology V |
Paul Noble |
Innate Immune Regulation of Lung Alveolar Stem Cell Renewal in Mouse and Man |
$617,662 |
|
Disease Team Therapy Development - Research |
Clive Svendsen |
Progenitor Cells Secreting GDNF for the Treatment of ALS |
$16,168,464 |
|
Clinical Trial Stage Projects |
Michael Lewis |
Pulmonary Arterial Hypertension Treated with Cardiosphere-Derived Allogeneic Stem Cells |
$7,354,772 |
|
Disease Team Planning |
Eduardo Marbán |
{REDACTED} Heart Disease Regenerative Medicine Team Planning Award |
$38,980 |
|
iPSC Consortia Award |
Clive Svendsen |
The HD iPSC Consortium: Repeat Length Dependent Phenotypes for Assay Development |
$300,000 |
|
Conference |
John Yu |
First Annual Stem Cell Therapies for Neurological Disorders: Overcoming the Current Barriers to Clinical Translation, April 30 (special stem cell program for high school students on April 28) |
$18,500 |
|
Early Translational II |
Dan Gazit |
Systemic Adult Stem Cell Therapy for Osteoporosis-Related Vertebral Compression Fractures |
$1,927,698 |
|
Transplantation Immunology |
Terrence Town |
Role of HLA in neural stem cell rejection using humanized mice |
$1,119,385 |
|
Basic Biology IV |
Eduardo Marbán |
Mechanism of heart regeneration by cardiosphere-derived cells |
$1,367,604 |
|
Conference |
Clive Svendsen |
California ALS Summit 2012 |
$6,825 |
|
Disease Team Research I |
Eduardo Marbán |
Autologous cardiac-derived cells for advanced ischemic cardiomyopathy |
$5,560,232 |
|
Late Stage Preclinical Projects |
Shaomei Wang |
IND-enabling study of subretinal delivery of human neural progenitor cells for the treatment of retinitis pigmentosa |
$4,954,514 |
|
New Faculty Physician Scientist |
Robert Baloh |
Human iPSC modeling and therapeutics for degenerative peripheral nerve disease |
$3,031,737 |
